Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jenningseastera完成签到,获得积分0
刚刚
向左转完成签到 ,获得积分10
1秒前
友好翠安完成签到,获得积分10
1秒前
Zeno完成签到 ,获得积分20
1秒前
灵巧忆南完成签到,获得积分10
1秒前
Yiwaa完成签到,获得积分10
1秒前
JT发布了新的文献求助10
2秒前
L3完成签到,获得积分10
2秒前
2秒前
卓向梦发布了新的文献求助10
2秒前
xiaoqiao发布了新的文献求助10
2秒前
yy的应助被silica347采纳,获得10
2秒前
平平完成签到,获得积分10
3秒前
凡城完成签到,获得积分10
3秒前
一只小鲨鱼完成签到,获得积分10
4秒前
4712完成签到,获得积分10
4秒前
轩轩完成签到 ,获得积分10
4秒前
小田完成签到,获得积分10
4秒前
5秒前
尹山蝶完成签到,获得积分0
5秒前
DrLee发布了新的文献求助10
6秒前
6秒前
啦啦啦完成签到,获得积分10
6秒前
6秒前
优秀丹琴完成签到,获得积分10
6秒前
潘锦麒完成签到 ,获得积分10
6秒前
7秒前
Shi完成签到,获得积分10
7秒前
Star完成签到,获得积分10
7秒前
sure完成签到 ,获得积分10
7秒前
天晴的应助被dd采纳,获得10
7秒前
淮雨巷陌发布了新的文献求助10
8秒前
8秒前
yzee完成签到,获得积分10
8秒前
可爱的函函的应助被xxx采纳,获得10
8秒前
知性的寄真完成签到,获得积分10
8秒前
xyx2999完成签到,获得积分10
8秒前
苗条秋荷完成签到,获得积分10
8秒前
keyan完成签到 ,获得积分10
9秒前
呀呀呀呀发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Modern Artificial Intelligence 1000
Особенности технологий и методов информационно-психологических войн СССР с Великобританией и США в период 1939-1953 гг 1000
Das Matthäusevangelium: Kapitel 1:1–17 1000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Entre Praga y Madrid : los contactos checoslovaco-españoles (1948-1977) 600
A REVIEW OF THE V-22 DYNAMICS VALIDATION PROGRAM 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8130276
求助须知:如何正确求助?哪些是违规求助? 9532510
关于积分的说明 21596541
捐赠科研通 7712118
什么是DOI,文献DOI怎么找? 3418072
关于科研通互助平台的介绍 2543784
邀请新用户注册赠送积分活动 2459347